Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hepatitis B virus large surface antigen (LHBsAg) is one of three isoforms of the hepatitis B surface antigen (HBsAg), forming the viral envelope. LHBsAg is a multifunctional glycoprotein crucial for viral entry, immune evasion, and pathogenesis. It binds to the host cell receptor NTCP, facilitates viral entry into hepatocytes, suppresses innate and adaptive immunity, and its accumulation can induce endoplasmic reticulum stress, promoting liver cancer. Its presence is a key marker for HBV infection, and mutations can lead to diagnostic and vaccine escape.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B Virus Large Surface Antigen (LHBsAg).